"In some cases, ReCell may be used as a standalone treatment for superficial burns that do not require a widely meshed autograft"
Those cases don't need Recell. They will heal just fine by themselves.
The company has been pushing this "super user" concept beyond it's appropriate use to generate more revenue at unnecessary cost to patients.
Read the NICE expert panel assessment. I agree with it. The evidence to support the company claims is weak as dish water
Ann: AVITA Medical to Announce First Quarter 2023 Results, page-28
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.02 |
Change
-0.060(1.95%) |
Mkt cap ! $212.6M | |||
| Open | High | Low | Value | Volume |
| $3.08 | $3.08 | $3.00 | $225.1K | 74.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1120 | $3.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.03 | 500 | 1 |
View Market Depth
| Last trade - 15.35pm 27/09/2024 (20 minute delay) ? |
| AVH (ASX) Chart |